2022
Predictors of Recurrent Venous Thrombosis After Cerebral Venous Thrombosis
Shu L, Bakradze E, Omran SS, Giles J, Amar J, Henninger N, Elnazeir M, Liberman A, Moncrieffe K, Rotblat J, Sharma R, Cheng Y, Zubair AS, Simpkins A, Li G, Kung J, Perez D, Heldner MR, Scutelnic A, von Martial R, Siepen B, Rothstein A, Khazaal O, Do D, Al Kasab S, Rahman LA, Mistry EA, Kerrigan D, Lafever H, Nguyen TN, Klein P, Aparicio HJ, Frontera JA, Kuohn L, Agarwal S, Stretz C, Kala N, ElJamal S, Chang A, Cutting S, Indraswari F, de Havenon A, Muddasani V, Wu T, Wilson D, Nouh A, Asad D, Qureshi A, Moore J, Khatri P, Aziz Y, Casteigne B, Khan M, Cheng Y, Grory BM, Weiss M, Ryan D, Vedovati MC, Paciaroni M, Siegler J, Kamen S, Yu S, Guerrero CL, Atallah E, De Marchis GM, Brehm A, Dittrich T, Psychogios M, Alvarado-Dyer R, Kass-Hout T, Prabhakaran S, Honda T, Liebeskind D, Furie K, Yaghi S. Predictors of Recurrent Venous Thrombosis After Cerebral Venous Thrombosis. Neurology 2022, 99: e2368-e2377. PMID: 36123126, PMCID: PMC9687409, DOI: 10.1212/wnl.0000000000201122.Peer-Reviewed Original ResearchConceptsCerebral venous thrombosisRecurrent venous thrombosisHistory of VTEVenous thrombosisVenous thromboembolismAntiphospholipid antibodiesBlack raceDiagnosis of CVTPositive antiphospholipid antibodiesRecurrent venous thrombosesAntiphospholipid antibody syndromeRecurrent venous thromboembolismCox regression analysisRisk of recurrenceMulticenter international studyAntibody syndromeOral anticoagulationVenous thrombosesConsecutive patientsRare causeMean ageTreatment strategiesThrombosisPatientsSecondary analysisDirect Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study
Yaghi S, Shu L, Bakradze E, Omran S, Giles JA, Amar JY, Henninger N, Elnazeir M, Liberman AL, Moncrieffe K, Lu J, Sharma R, Cheng Y, Zubair AS, Simpkins AN, Li GT, Kung JC, Perez D, Heldner M, Scutelnic A, Seiffge D, Siepen B, Rothstein A, Khazaal O, Do D, Al Kasab S, Rahman LA, Mistry EA, Kerrigan D, Lafever H, Nguyen TN, Klein P, Aparicio H, Frontera J, Kuohn L, Agarwal S, Stretz C, Kala N, Jamal S, Chang A, Cutting S, Xiao H, de Havenon A, Muddasani V, Wu T, Wilson D, Nouh A, Asad SD, Qureshi A, Moore J, Khatri P, Aziz Y, Casteigne B, Khan M, Cheng Y, Mac Grory B, Weiss M, Ryan D, Vedovati MC, Paciaroni M, Siegler JE, Kamen S, Yu S, Guerrero C, Atallah E, De Marchis GM, Brehm A, Dittrich T, Psychogios M, Alvarado-Dyer R, Kass-Hout T, Prabhakaran S, Honda T, Liebeskind DS, Furie K. Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study. Stroke 2022, 53: 728-738. PMID: 35143325, DOI: 10.1161/strokeaha.121.037541.Peer-Reviewed Original ResearchConceptsCerebral venous thrombosisDirect oral anticoagulantsVenous thrombosisRecurrent venous thrombosisMajor hemorrhageInclusion criteriaDirect Oral Anticoagulants Versus WarfarinMulticenter international retrospective studyInverse probabilityInternational retrospective studySystemic venous thrombosisFavorable safety profileCox regression modelMulticenter international studyAnalysis inclusion criteriaBaseline imaging dataCVT patientsOral anticoagulationComplete recanalizationDOAC treatmentOral anticoagulantsRadiological outcomesRadiographic outcomesVersus WarfarinWarfarin treatment
2021
Blood Pressure Trajectory Groups and Outcome After Endovascular Thrombectomy: A Multicenter Study
Petersen NH, Kodali S, Meng C, Li F, Nguyen CK, Peshwe KU, Strander S, Silverman A, Kimmel A, Wang A, Anadani M, Almallouhi E, Spiotta AM, Kim JT, Giles JA, Keyrouz SG, Farooqui M, Zevallos C, Maier IL, Psychogios MN, Liman J, Riou-Comte N, Richard S, Gory B, Wolfe S, Brown PA, Fargen KM, Mistry EA, Fakhri H, Mistry AM, Wong KH, de Havenon A, Nascimento FA, Kan P, Matouk C, Ortega-Gutiérrez S, Sheth KN. Blood Pressure Trajectory Groups and Outcome After Endovascular Thrombectomy: A Multicenter Study. Stroke 2021, 53: 1216-1225. PMID: 34781705, PMCID: PMC8960326, DOI: 10.1161/strokeaha.121.034408.Peer-Reviewed Original ResearchConceptsSymptomatic intracranial hemorrhageEndovascular thrombectomyBlood pressure trajectoriesFunctional outcomeHemorrhagic transformationIschemic strokeSBP trajectoriesIntracranial hemorrhageAnterior circulation large vessel occlusion ischemic strokeModified Rankin Scale (mRS) 90 daysTrajectory groupsLarge vessel occlusion ischemic strokeMulticenter retrospective cohort studySystolic blood pressure trajectoriesBlood pressure courseOptimal hemodynamic managementSBP trajectory groupsRetrospective cohort studyAcute ischemic strokeElevated blood pressurePoor functional outcomePressure trajectoriesBlood pressure dataCohort studySecondary outcomes
2020
Anticoagulation Type and Early Recurrence in Cardioembolic Stroke
Yaghi S, Mistry E, Liberman AL, Giles J, Asad SD, Liu A, Nagy M, Kaushal A, Azher I, Mac Grory B, Fakhri H, Brown Espaillat K, Pasupuleti H, Martin H, Tan J, Veerasamy M, Esenwa C, Cheng N, Moncrieffe K, Moeini-Naghani I, Siddu M, Scher E, Trivedi T, Lord A, Furie K, Keyrouz S, Nouh A, Leon Guerrero CR, de Havenon A, Khan M, Henninger N. Anticoagulation Type and Early Recurrence in Cardioembolic Stroke. Stroke 2020, 51: 2724-2732. PMID: 32757753, PMCID: PMC7484360, DOI: 10.1161/strokeaha.120.028867.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnticoagulantsAtrial FibrillationBrain IschemiaEmbolismFemaleHeart DiseasesHeparin, Low-Molecular-WeightHumansIncidenceIntracranial HemorrhagesMaleMiddle AgedNeuroimagingRecurrenceRegistriesRetrospective StudiesRisk AssessmentStrokeTreatment OutcomeUnited StatesWarfarinConceptsSymptomatic intracranial hemorrhageRecurrent ischemic eventsLow molecular weight heparinAcute ischemic strokeMolecular weight heparinIschemic eventsIntracranial hemorrhageIschemic strokeAtrial fibrillationAnalysis inclusion criteriaEarly recurrenceWeight heparinInclusion criteriaSeparate Cox regression analysesComprehensive stroke centerLarge prospective studiesOral anticoagulant therapyCox regression analysisCox regression modelAnticoagulation typeDOAC treatmentStroke RegistryAnticoagulant therapyCardioembolic strokeStroke centers
2019
Blood pressure reduction and outcome after endovascular therapy with successful reperfusion: a multicenter study
Anadani M, Arthur AS, Alawieh A, Orabi Y, Alexandrov A, Goyal N, Psychogios MN, Maier I, Kim JT, Keyrouz SG, de Havenon A, Petersen NH, Pandhi A, Swisher CB, Inamullah O, Liman J, Kodali S, Giles JA, Allen M, Wolfe SQ, Tsivgoulis G, Cagle BA, Oravec CS, Gory B, De Marini P, Kan P, Rahman S, Richard S, Nascimento FA, Spiotta A. Blood pressure reduction and outcome after endovascular therapy with successful reperfusion: a multicenter study. Journal Of NeuroInterventional Surgery 2019, 12: 932-936. PMID: 31806668, PMCID: PMC7998040, DOI: 10.1136/neurintsurg-2019-015561.Peer-Reviewed Original ResearchConceptsSBP reductionSystolic blood pressureSuccessful reperfusionMechanical thrombectomyPoor outcomeSafety outcomesAnterior circulation large vessel occlusionElevated systolic blood pressureModified Rankin Scale scoreBlood pressure reductionComprehensive stroke centerSymptomatic intracerebral hemorrhageAcute ischemic strokeMulticenter retrospective studyRankin Scale scoreLarge vessel occlusionIncomplete reperfusionReperfusion statusSafety endpointIschemic strokeStroke centersBlood pressureComplete reperfusionEndovascular therapyIntracerebral hemorrhage